CureVac, bruised from its COVID-19 vaccine woes, has struck another deal to bolster its cancer vaccine development capabilities, buying Frame Cancer Therapeutics for its ability to identify unique and shared neoantigens.
[Fierce Biotech]
Home Newsletters Human Immunology News Back in the Frame: CureVac Inks Biotech Buyout to Step Up Cancer...
